ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
Previous Symbol
CUSIP16383L10
Phone650-210-2900
Debt
Debt-to-Equity Ratio0.69
Current Ratio2.87
Quick Ratio2.87
Price-To-Earnings
Trailing P/E Ratio28.03
Forward P/E Ratio-12.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$82.50 million
Price / Sales6.17
Cash Flow$0.3624 per share
Price / Cash Flow27.79
Book Value$1.63 per share
Price / Book6.18
Profitability
EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net Margins13.88%
Return on Equity32.16%
Return on Assets6.49%
Miscellaneous
Employees66
Outstanding Shares50,530,000
Market Cap$525.97 million
OptionableOptionable
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx Inc (NASDAQ:CCXI) posted its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The biopharmaceutical company had revenue of $8.98 million for the quarter, compared to the consensus estimate of $11.55 million. ChemoCentryx had a net margin of 13.88% and a return on equity of 32.16%. View ChemoCentryx's Earnings History.
When is ChemoCentryx's next earnings date?
What price target have analysts set for CCXI?
6 brokers have issued 1 year price targets for ChemoCentryx's stock. Their forecasts range from $12.50 to $20.00. On average, they expect ChemoCentryx's share price to reach $17.10 in the next year. This suggests a possible upside of 68.3% from the stock's current price. View Analyst Price Targets for ChemoCentryx.
What is the consensus analysts' recommendation for ChemoCentryx?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 3 hold ratings, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.
What are Wall Street analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year end 2018 net cash of $2.49/ share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (8/13/2018)
- 2. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (7/16/2018)
Has ChemoCentryx been receiving favorable news coverage?
Press coverage about CCXI stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ChemoCentryx earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the near term.
Are investors shorting ChemoCentryx?
ChemoCentryx saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 1,443,448 shares, a decrease of 40.8% from the October 31st total of 2,439,799 shares. Based on an average trading volume of 158,408 shares, the short-interest ratio is currently 9.1 days. Currently, 4.8% of the shares of the company are short sold. View ChemoCentryx's Current Options Chain.
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Heron Therapeutics (HRTX), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Endocyte (ECYT), Supernus Pharmaceuticals (SUPN), Pacira Pharmaceuticals (PCRX), AnaptysBio (ANAB), Opko Health (OPK), Zogenix (ZGNX), Reata Pharmaceuticals (RETA), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), PTC Therapeutics (PTCT), Madrigal Pharmaceuticals (MDGL) and Mallinckrodt (MNK).
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 59)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 55)
- Dr. Rajinder Singh, Sr. VP of Research (Age 51)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 65)
- Dr. Markus J. Cappel, Chief Bus. Officer & Treasurer (Age 57)
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.57%), Wasatch Advisors Inc. (4.75%), Franklin Resources Inc. (2.86%), Vanguard Group Inc. (2.63%), Vanguard Group Inc (2.63%) and Acadian Asset Management LLC (1.78%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Plc Glaxosmithkline, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which institutional investors are selling ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., TIAA CREF Investment Management LLC, Virtus ETF Advisers LLC, Bridgeway Capital Management Inc., Strs Ohio and Keybank National Association OH. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Plc Glaxosmithkline, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.
Which institutional investors are buying ChemoCentryx stock?
CCXI stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Fosun International Ltd, Acadian Asset Management LLC, GSA Capital Partners LLP, Cadence Capital Management LLC, Vanguard Group Inc, Vanguard Group Inc. and BlackRock Inc.. View Insider Buying and Selling for ChemoCentryx.
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $10.16.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $525.97 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.
What is ChemoCentryx's official website?
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
